Advertisement

Current Colorectal Cancer Reports

, Volume 12, Issue 3, pp 151–161 | Cite as

Circulating Tumor Cells Versus Circulating Tumor DNA in Colorectal Cancer: Pros and Cons

  • Carlyn Rose C. Tan
  • Lanlan Zhou
  • Wafik S. El-DeiryEmail author
Translational Colorectal Oncology (Y Jiang, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Translational Colorectal Oncology

Abstract

Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) are emerging noninvasive multifunctional biomarkers in liquid biopsy allowing for early diagnosis, accurate prognosis, therapeutic target selection, spatiotemporal monitoring of metastasis, as well as monitoring response and resistance to treatment. CTCs and ctDNA are released from different tumor types at different stages and contribute complementary information for clinical decision. Although big strides have been taken in technology development for detection, isolation and characterization of CTCs and sensitive and specific detection of ctDNA, CTC-, and ctDNA-based liquid biopsies may not be widely adopted for routine cancer patient care until the suitability, accuracy, and reliability of these tests are validated and more standardized protocols are corroborated in large, independent, prospectively designed trials. This review covers CTC- and ctDNA-related technologies and their application in colorectal cancer. The promise of CTC- and ctDNA-based liquid biopsies is envisioned.

Keywords

Circulating tumor cells (CTCs) Circulating tumor DNA (ctDNA) Colorectal cancer (CRC) Liquid biopsy Tumor heterogeneity CTC enrichment Positive selection Negative selection Precision medicine Resistance mechanism 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    American Cancer Society. Cancer facts & figures 2015. Atlanta: American Cancer Society; 2015.Google Scholar
  2. 2.
    American Cancer Society. Colorectal cancer facts & figures 2014-2016. Atlanta: American Cancer Society; 2014.Google Scholar
  3. 3.
    Ashworth TR. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust Med J. 1869; 146-149.Google Scholar
  4. 4.
    Mandel P, Metais P. Les acides nucleiques du plasma sanguin ches l’homme. C R Seances Soc Biol Fil. 1948;142(3-4):241–3.PubMedGoogle Scholar
  5. 5.•
    Bork U et al. Circulating tumour cells and outcome in non-metastatic colorectal cancer: a prospective study. Br J Cancer. 2015;112(8):1306–13. Prospective study evaluating the role of CTCs in patients with non-metastatic CRC. Preoperative CTC detection is a strong prognostic marker and is associated with worse OS in the non-metastatic CRC setting.Google Scholar
  6. 6.
    Cohen SJ et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(19):3213–21.CrossRefPubMedGoogle Scholar
  7. 7.
    Cristofanilli M et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351(8):781–91.CrossRefPubMedGoogle Scholar
  8. 8.
    de Bono JS et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14(19):6302–9.CrossRefPubMedGoogle Scholar
  9. 9.•
    Cayrefourcq L et al. Establishment and characterization of a cell line from human circulating colon cancer cells. Cancer Res. 2015;75(5):892–901. Study describing the first successful establishment of cell cultures and a permanent cell line from CTCs of a CRC patient. The cells have been characterized at the genome, transcriptome, proteome, and secretome levels.Google Scholar
  10. 10.•
    Aceto N et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014;158(5):1110–22. Study to define the origin and functional properties of CTC clusters. CTC clusters originate as oligoclonal groups of cells from the primary tumor that exhibit increased metastatic propensity compared to single CTCs. Abundance of CTC clusters in the peripheral blood is associated with adverse outcomes.Google Scholar
  11. 11.
    Cho EH et al. Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors. Phys Biol. 2012;9(1):016001.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Stott SL et al. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A. 2010;107(43):18392–7.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Adams DL et al. Circulating giant macrophages as a potential biomarker of solid tumors. Proc Natl Acad Sci U S A. 2014;111(9):3514–9.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Best MG et al. RNA-Seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics. Cancer Cell. 2015;28(5):666–76.Google Scholar
  15. 15.
    Goldberg GS et al. Global effects of anchorage on gene expression during mammary carcinoma cell growth reveal role of tumor necrosis factor-related apoptosis-inducing ligand in anoikis. Cancer Res. 2001;61(4):1334–7.PubMedGoogle Scholar
  16. 16.
    Krivacic RT et al. A rare-cell detector for cancer. Proc Natl Acad Sci U S A. 2004;101(29):10501–4.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Campton DE, Ramirez AB, Nordberg JJ, Drovetto N, Clein AC, Varshavskaya P, et al. High-recovery visual identification and single-cell retrieval of circulating tumor cells for genomic analysis using a dual-technology platform integrated with automated immunofluorescence staining. BMC Cancer. 2015;15:360.Google Scholar
  18. 18.
    Werner SL et al. Analytical validation and capabilities of the Epic CTC platform: enrichment-free circulating tumour cell detection and characterization. J Circ Biomark. 2015;4:3.Google Scholar
  19. 19.
    Tan SJ et al. Microdevice for the isolation and enumeration of cancer cells from blood. Biomed Microdevices. 2009;11(4):883–92.CrossRefPubMedGoogle Scholar
  20. 20.
    Harouaka RA et al. Flexible micro spring array device for high-throughput enrichment of viable circulating tumor cells. Clin Chem. 2014;60(2):323–33.CrossRefPubMedGoogle Scholar
  21. 21.
    Gallant JN et al. Predicting therapy response in live tumor cells isolated with the flexible micro spring array device. Cell Cycle. 2013;12(13):2132–43.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Adams DL et al. Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the CellSearch® CTC test. Cytometry A. 2015;87(2):137–44.CrossRefPubMedGoogle Scholar
  23. 23.
    Pinzani P et al. Isolation by size of epithelial tumor cells in peripheral blood of patients with breast cancer: correlation with real-time reverse transcriptase-polymerase chain reaction results and feasibility of molecular analysis by laser microdissection. Hum Pathol. 2006;37(6):711–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Xu L et al. Optimization and evaluation of a novel size based circulating tumor cell isolation system. PLoS One. 2015;10(9), e0138032.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Kaifi JT et al. Circulating tumor cell isolation during resection of colorectal cancer lung and liver metastases: a prospective trial with different detection techniques. Cancer Biol Ther. 2015;16(5):699–708.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Obermayr E et al. Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients. BMC Cancer. 2010;10:666.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Clawson GA et al. Circulating tumor cells in melanoma patients. PLoS One. 2012;7(7), e41052.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Gupta V et al. ApoStream™, a new dielectrophoretic device for antibody independent isolation and recovery of viable cancer cells from blood. Biomicrofluidics. 2012;6(2):24133.CrossRefPubMedGoogle Scholar
  29. 29.
    Antfolk M et al. Acoustofluidic, label-free separation and simultaneous concentration of rare tumor cells from white blood cells. Anal Chem. 2015;87(18):9322–8.CrossRefPubMedGoogle Scholar
  30. 30.
    Li P et al. Acoustic separation of circulating tumor cells. Proc Natl Acad Sci U S A. 2015;112(16):4970–5.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Miller MC, Doyle GV, Terstappen LW. Significance of circulating tumor cells detected by the cell search system in patients with metastatic breast colorectal and prostate cancer. J Oncol. 2010;2010:617421.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Swennenhuis JF, Terstappen L. Sample preparation methods following cell search approach compatible of single-cell whole-genome amplification: an overview. Methods Mol Biol. 2015;1347:57–67.CrossRefPubMedGoogle Scholar
  33. 33.
    Pestrin M et al. Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients. Mol Oncol. 2015;9(4):749–57.CrossRefPubMedGoogle Scholar
  34. 34.
    Talasaz AH et al. Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc Natl Acad Sci U S A. 2009;106(10):3970–5.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Zieglschmid V et al. Combination of immunomagnetic enrichment with multiplex RT-PCR analysis for the detection of disseminated tumor cells. Anticancer Res. 2005;25(3A):1803–10.PubMedGoogle Scholar
  36. 36.
    Saliba AE et al. Microfluidic sorting and multimodal typing of cancer cells in self-assembled magnetic arrays. Proc Natl Acad Sci U S A. 2010;107(33):14524–9.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Harb W, et al. Mutational analysis of circulating tumor cells using a novel microfluidic collection device and qPCR assay. Transl Oncol. 2013; 6(5): 528–38.Google Scholar
  38. 38.
    Galanzha EI, Zharov VP. Circulating tumor cell detection and capture by photoacoustic flow cytometry in vivo and ex vivo. Cancers (Basel). 2013;5(4):1691–738.CrossRefGoogle Scholar
  39. 39.
    Saucedo-Zeni N et al. A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire. Int J Oncol. 2012;41(4):1241–50.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Hyun KA, Lee TY, Jung HI. Negative enrichment of circulating tumor cells using a geometrically activated surface interaction chip. Anal Chem. 2013;85(9):4439–45.CrossRefPubMedGoogle Scholar
  41. 41.
    Ozkumur E et al. Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med. 2013;5(179):179ra47.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Yu M et al. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science. 2014;345(6193):216–20.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Hyun KA et al. Two-stage microfluidic chip for selective isolation of circulating tumor cells (CTCs). Biosens Bioelectron. 2015;67:86–92.CrossRefPubMedGoogle Scholar
  44. 44.
    Deneve E et al. Capture of viable circulating tumor cells in the liver of colorectal cancer patients. Clin Chem. 2013;59(9):1384–92.CrossRefPubMedGoogle Scholar
  45. 45.
    Groot Koerkamp B et al. Circulating tumor cells and prognosis of patients with resectable colorectal liver metastases or widespread metastatic colorectal cancer: a meta-analysis. Ann Surg Oncol. 2013;20(7):2156–65.CrossRefPubMedGoogle Scholar
  46. 46.
    Rahbari NN et al. Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. Gastroenterology. 2010;138(5):1714–26.CrossRefPubMedGoogle Scholar
  47. 47.
    Cohen SJ et al. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol. 2009;20(7):1223–9.CrossRefPubMedGoogle Scholar
  48. 48.
    Matsusaka S et al. Circulating tumor cells as a surrogate marker for determining response to chemotherapy in Japanese patients with metastatic colorectal cancer. Cancer Sci. 2011;102(6):1188–92.CrossRefPubMedGoogle Scholar
  49. 49.•
    Sastre J et al. Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. Oncologist. 2012;17(7):947–55. Prospective ancillary study of the Maintenance in Colorectal Cancer trial to evaluate the CTC count as a prognostics and/or predictive marker for efficacy endpoints. CTC enumeration is a strong prognostic factor for PFS and OS outcomes and an indicator of treatment response in mCRC patients receiving XELOX +/− bevacizumab.Google Scholar
  50. 50.
    Kawahara H et al. Determination of circulating tumor cells for prediction of recurrent colorectal cancer progression. Hepatogastroenterology. 2012;59(119):2115–8.PubMedGoogle Scholar
  51. 51.
    Tol J et al. Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Ann Oncol. 2010;21(5):1006–12.CrossRefPubMedGoogle Scholar
  52. 52.
    Garrigós N et al. Circulating tumour cell analysis as an early marker for relapse in stage II and III colorectal cancer patients: a pilot study. Clin Transl Oncol. 2010;12(2):142–7.CrossRefPubMedGoogle Scholar
  53. 53.
    Lu CY et al. Circulating tumor cells as a surrogate marker for determining clinical outcome to mFOLFOX chemotherapy in patients with stage III colon cancer. Br J Cancer. 2013;108(4):791–7.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Wong SC et al. Clinical significance of cytokeratin 20-positive circulating tumor cells detected by a refined immunomagnetic enrichment assay in colorectal cancer patients. Clin Cancer Res. 2009;15(3):1005–12.CrossRefPubMedGoogle Scholar
  55. 55.•
    Ning Y et al. Cytokeratin-20 and survivin-expressing circulating tumor cells predict survival in metastatic colorectal cancer patients by a combined immunomagnetic qRT-PCR approach. Mol Cancer Ther. 2015;14(10):2401–8. Study evaluating the prognostic value of baseline CTC CK20 and survivin expression in mCRC patients. CTC CK20 and survivin expression effectively predict OS in mCRC patients receiving chemotherapy.Google Scholar
  56. 56.
    Iinuma H et al. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes’ stage B and C colorectal cancer. J Clin Oncol. 2011;29(12):1547–55.CrossRefPubMedGoogle Scholar
  57. 57.
    Walther A et al. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer. 2009;9(7):489–99.CrossRefPubMedGoogle Scholar
  58. 58.
    Gasch C et al. Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. Clin Chem. 2013;59(1):252–60.CrossRefPubMedGoogle Scholar
  59. 59.•
    Heitzer E et al. Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res. 2013;73(10):2965–75. This study conducted the first comprehensive genomic profiling of CTCs using CGH and next-generation sequencing. Genomic profiling of CTCs is feasible. Most mutations thought initially to be exclusive to CTCs were present at a subclonal level in the primary tumor and/or metastasis suggesting that CTCs can be used to elucidate changes in the tumor genome that was either not present or observed at the time of initial diagnosis and can be used to tailor management.Google Scholar
  60. 60.
    Schölch S et al. Circulating tumor cells of colorectal cancer. Cancer Cell Microenviron. 2014;1(5):1–6.Google Scholar
  61. 61.
    Buim ME et al. Detection of KRAS mutations in circulating tumor cells from patients with metastatic colorectal cancer. Cancer Biol Ther. 2015;16(9):1289–95.CrossRefPubMedGoogle Scholar
  62. 62.
    Dawson SJ et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013;368(13):1199–209.CrossRefPubMedGoogle Scholar
  63. 63.
    Freidin MB et al. Circulating tumor DNA outperforms circulating tumor cells for KRAS mutation detection in thoracic malignancies. Clin Chem. 2015;61(10):1299–304.CrossRefPubMedGoogle Scholar
  64. 64.
    Yates LR, Campbell PJ. Evolution of the cancer genome. Nat Rev Genet. 2012;13(11):795–806.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.•
    Siravegna G et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med. 2015;21(7):795–801. Study using ctDNA to genotype colorectal cancer tumors and track clonal evolution during treatment with EGFR-specific antibodies. This study showed that mutated KRAS clones that emerge in the blood during EGFR blockade decline upon withdrawal of EGFR-specific anitbodies, indicating clonal evolution and that the CRC genome adapts dynamically to intermittent drug schedules.Google Scholar
  66. 66.
    Murtaza M et al. Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. Nat Commun. 2015;6:8760.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Sonnenberg A et al. Rapid electrokinetic isolation of cancer-related circulating cell-free DNA directly from blood. Clin Chem. 2014;60(3):500–9.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Yeh CH et al. Next-generation sequencing analysis of high-quality and high-quantity cell-free circulating DNA prepared from droplet volumes of patient plasma. J Clin Oncol. 2015;33(15_suppl):abstr e22008.Google Scholar
  69. 69.
    Spindler KL et al. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin Cancer Res. 2012;18(4):1177–85.CrossRefPubMedGoogle Scholar
  70. 70.
    Vogelstein B, Kinzler KW. Digital PCR. Proc Natl Acad Sci U S A. 1999;96(16):9236–41.CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.•
    Taly V et al. Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. Clin Chem. 2013;59(12):1722–31. Study demonstrating the feasibility and utility of multiplex dPCR of plasma DNA to screen for 7 common mutations in KRAS codons 12 and 13 in patients with mCRC.Google Scholar
  72. 72.
    Sefrioui D et al. Clinical value of chip-based digital-PCR platform for the detection of circulating DNA in metastatic colorectal cancer. Dig Liver Dis. 2015;47(10):884–90.CrossRefPubMedGoogle Scholar
  73. 73.
    Diehl F et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985–90.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Dressman D et al. Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A. 2003;100(15):8817–22.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Liu Q, Sommer SS. Pyrophosphorolysis-activated polymerization (PAP): application to allele-specific amplification. Biotechniques. 2000;29(5):1072–6. 1078, 1080 passim.PubMedGoogle Scholar
  76. 76.
    Bettegowda C et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24.CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.•
    Forshew T et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med. 2012;4(136):136ra68. Study evaluating TAm-Seq of ctDNA as a noninvasive method to screen for low-frequency mutations. This method identified cancer mutations present in ctDNA at allele frequencies as low as 2% with sensitivity and specificity >97%.Google Scholar
  78. 78.•
    Newman AM et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014;20(5):548–54. Study evaluating the utility and feasibility of CAPP-Seq to detect and quantify ctDNA with broad patient coverage. CAPP-Seq allows for highly sensitive and noninvasive detection of ctDNA in a majority of patients with NSCLC at low cost.Google Scholar
  79. 79.
    Kidess E et al. Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platform. Oncotarget. 2015;6(4):2549–61.CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Leary RJ et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med. 2012;4(162):162ra154.CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.•
    Murtaza M et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature. 2013;497(7447):108–12. Study evaluating exome-wide sequencing using ctDNA. Exome-wide sequencing of ctDNA is feasible and can be used to track genomic evolution of metastatic cancers in response to therapy.Google Scholar
  82. 82.
    Diehl F et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A. 2005;102(45):16368–73.CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    Wang JY et al. Molecular detection of APC, K- ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers. World J Surg. 2004;28(7):721–6.CrossRefPubMedGoogle Scholar
  84. 84.
    Frattini M et al. Quantitative analysis of plasma DNA in colorectal cancer patients: a novel prognostic tool. Ann N Y Acad Sci. 2006;1075:185–90.CrossRefPubMedGoogle Scholar
  85. 85.
    Schwarzenbach H et al. Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer. Ann N Y Acad Sci. 2008;1137:190–6.CrossRefPubMedGoogle Scholar
  86. 86.•
    Diaz LA et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012;486(7404):537–40. Study evaluating the evolution of mutant KRAS ctDNA in patients receiving panitumumab. Thirty-eight percent of patients whose tumors were initially KRAS wild type developed KRAS mutations detected by ctDNA. Mathematical modelling indicated that the mutations were present in expanded subclones before the initiation of panitumumab suggesting that the emergence of KRAS mutations is a mediator of acquired resistance to EGFR blockade and it is feasible to detect these mutations in a non-invasive manner.Google Scholar
  87. 87.•
    Misale S et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486(7404):532–6. Study using ctDNA to show that molecular alterations of KRAS are causally associated with the onset of acquired resistance to anti-EGFR treatment in CRC. KRAS mutant alleles were detectable in blood as early as 10 months before radiographic evidence of disease progression. The study identifies KRAS mutations as frequent drivers of acquired resistance to cetuximab in CRC and show that the emergence of KRAS mutant clones can be detected as ctDNA non-invasively months prior to radiographic progression.Google Scholar
  88. 88.
    Trevisiol C et al. Prognostic value of circulating KRAS2 gene mutations in colorectal cancer with distant metastases. Int J Biol Markers. 2006;21(4):223–8.PubMedGoogle Scholar
  89. 89.
    Fleischhacker M, Schmidt B. Circulating nucleic acids (CNAs) and cancer—a survey. Biochim Biophys Acta. 2007;1775(1):181–232.PubMedGoogle Scholar
  90. 90.
    Das A et al. Clinico-pathological correlation of serial measurement of circulating tumor cells in 24 metastatic colorectal cancer patients receiving chemotherapy reveals interpatient heterogeneity correlated with CEA levels but independent of KRAS and BRAF mutation. Cancer Biol Ther. 2015;16(5):709–13.CrossRefPubMedPubMedCentralGoogle Scholar
  91. 91.
    Bertotti A et al. The genomic landscape of response to EGFR blockade in colorectal cancer. Nature. 2015;526(7572):263–7.CrossRefPubMedGoogle Scholar
  92. 92.
    Gao D et al. Organoid cultures derived from patients with advanced prostate cancer. Cell. 2014;159(1):176–87.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Carlyn Rose C. Tan
    • 1
  • Lanlan Zhou
    • 1
  • Wafik S. El-Deiry
    • 1
    Email author
  1. 1.Department of Hematology/Oncology and Molecular Therapeutics ProgramFox Chase Cancer CenterPhiladelphiaUSA

Personalised recommendations